GlassScriptPhysician profile
Farhad B Nowzari
NPI 1225059108
$12,086.93
in general payments reported to CMS, 2019-2025
47 companies · $5,442 in 2025
The $5,442 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $826 · 2021: $881 · 2022: $1,269 · 2023: $1,474 · 2024: $1,067 · 2025: $5,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,828 · Food and Beverage: $2,755 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,828.06 |
| Food and Beverage | $2,754.71 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $4,828.06 | 2025 | Oes Cystonephrofiberscope |
| Teleflex LLC | $1,174.90 | 2021-2025 | Urolift, Barrigel |
| Myriad Genetic Laboratories, INC. | $1,076.51 | 2021-2025 | Prolaris, Myrisk |
| Neotract INC. | $834.07 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $416.78 | 2023-2025 | Gemtesa |
| Zoll Medical Corporation | $400.00 | 2023 | |
| Endo Pharmaceuticals INC. | $347.69 | 2019-2024 | Xiaflex |
| Boston Scientific Corporation | $296.21 | 2019-2024 | Rezum Generator |
| Coloplast Corp | $273.07 | 2020-2025 | Titan, Altis |
| Janssen Biotech, INC. | $252.57 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Astellas Pharma US INC | $198.32 | 2019-2022 | |
| Urovant Sciences INC | $151.43 | 2021-2022 | |
| Procept Biorobotics Corporation | $145.31 | 2021-2023 | Aquabeam Robotic System |
| Pfizer INC. | $141.12 | 2019-2024 | |
| Progenics Pharmaceuticals, INC. | $115.47 | 2022-2024 |
Show all 45 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,379,273.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farhad Nowzari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.